logo
Plus   Neg
Share
Email

Regeneron & Sanofi: Dupixent Approved For Severe Asthma Indication In EU

Dupixent, which is being developed jointly by Regeneron and Sanofi, is now approved in the European Union for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation. Dupixent is also approved in the EU for the treatment of adults with moderate-to-severe atopic dermatitis.

Dupixent was approved last year in the U.S. as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The United Auto Workers union reportedly plans to go on strike against auto giant General Motors Co. (GM) after both the parties failed to reach a tentative deal before a Saturday deadline. According to CNBC, the strike has been called despite GM saying it presented a "strong offer" to the union.... Millennials and Generation Zs, or people aged between 18 to 34 year, pay more for car repairs, according to a new survey. The average American spent $1,986 over the past five years on vehicle repairs and maintenance, according to a survey by Ally Financial conducted by Harris Poll. However, among... Gap Inc.'s (GPS) Old Navy brand announced plans to open 800 new stores as part of its upcoming split from its parent company. "We'll almost double our fleet to 2,000 stores in North America, predominantly in under-served small markets," Old Navy CEO Sonia Syngal said. The company said the plan was...
Follow RTT